Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results

Upstream Bio (NASDAQ:UPB) announced its quarterly earnings results on Thursday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.06), FiscalAI reports. The company had revenue of $0.67 million during the quarter, compared to analysts’ expectations of $0.52 million. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 28.71%.

Upstream Bio Price Performance

NASDAQ UPB traded up $0.75 on Thursday, hitting $10.22. The stock had a trading volume of 52,022 shares, compared to its average volume of 1,325,713. The business’s fifty day moving average price is $16.80 and its 200 day moving average price is $21.50. Upstream Bio has a 52-week low of $5.14 and a 52-week high of $33.68. The stock has a market cap of $552.34 million, a price-to-earnings ratio of -5.38 and a beta of 2.96.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Lifesci Capital initiated coverage on Upstream Bio in a research report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Upstream Bio in a report on Wednesday, January 21st. Finally, Mizuho raised shares of Upstream Bio to a “strong-buy” rating in a research report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $45.25.

Institutional Trading of Upstream Bio

A number of institutional investors have recently made changes to their positions in UPB. AQR Capital Management LLC purchased a new position in Upstream Bio during the 1st quarter worth $115,000. Woodline Partners LP raised its stake in Upstream Bio by 5.8% in the first quarter. Woodline Partners LP now owns 557,063 shares of the company’s stock valued at $3,409,000 after buying an additional 30,552 shares during the last quarter. Creative Planning purchased a new stake in Upstream Bio in the second quarter valued at about $154,000. JPMorgan Chase & Co. boosted its holdings in Upstream Bio by 8.4% in the second quarter. JPMorgan Chase & Co. now owns 16,469 shares of the company’s stock worth $181,000 after acquiring an additional 1,275 shares in the last quarter. Finally, Legal & General Group Plc boosted its holdings in Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after acquiring an additional 1,440 shares in the last quarter.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.